Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxcarbazepine Plus Morphine in Refractory Cancer Pain
NCT02078089Phase 1Terminated
- Start
- Mar 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxcarbazepine in cancer pain. Primary endpoint: Number of patients with adverse events as a measure of safety and toxicity at 1 year. Started Mar 2014; status: terminated.
02
Drugs
oxcarbazepine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT02078089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078089.